logo
Three diets that are more effective than weight-loss drugs, according to doctors

Three diets that are more effective than weight-loss drugs, according to doctors

Yahoo2 days ago
The weight-loss jab boom is in full swing. With celebrities showing off dramatic transformations, #ozempicbody trending on TikTok, and many buying GLP-1 drugs like Mounjaro, Wegovy and Ozempic to slim down for beach holidays, it's estimated 1.5 million Britons are now using weight-loss drugs – with 95 per cent accessing them privately, from online pharmacies or weight-loss clinics.
There was good news recently for anyone hoping to try the latest weight-loss injections: the NHS announced that Mounjaro will now be available through GP surgeries in England for patients with severe obesity and the 'highest clinical need'. Over the next three years, almost a quarter of a million people are expected to benefit.
GLP-1 drugs, originally designed to treat type-2 diabetes, are widely hailed as a game changer for tackling obesity. Clinical trials suggest the jabs can help users lose 15-20 per cent of their body weight. They regulate blood-sugar levels and may improve conditions linked to excess weight, including high blood pressure, fatty liver disease and sleep apnoea.
However, as the Mounjaro rollout begins, concerns are mounting among doctors and public health experts that the GLP-1 gold rush is distracting from safer, more sustainable solutions for solving the UK's ailing metabolic health. Alongside the soaring demand, reports of GLP-1 side effects are growing: from nausea and constipation to gallbladder problems and, now, hundreds of cases of pancreatitis.
'There's been a rush to embrace GLP-1 drugs as a magic bullet, but we're not talking enough about the risks,' says Dr David Unwin, award-winning GP and scientific adviser to the Public Health Collaboration (PHC), a charity that champions lifestyle-based approaches to metabolic health. 'A BMJ investigation shows there have been 82 deaths associated with these medications. Yet most patients assume the drugs are safe. People are accessing them online, without proper medical supervision. It's like the Wild West.'
While he acknowledges GLP-1s have a role to play, he and other doctors are concerned the drugs are being promoted as a fix-all, and are quietly proving that targeted diet and lifestyle programmes can achieve similar results – without side effects.
'You can stimulate your own GLP-1, naturally, through food and exercise,' says Dr Unwin, who is known for pioneering the low-carb diet for obesity and diabetes in the UK. 'A low-carb, high-protein diet is shown to boost GLP-1 levels. And it doesn't come with nausea or cost a fortune.'
Dr Campbell Murdoch is a GP with a special interest in metabolic health who launched a Metabolic Health 28-Day Plan combining a high-protein, low-carb diet with time-restricted eating, movement, easy lifestyle changes and mindset support. Originally created for NHS patients at his practice in Somerset, the results were so positive, the programme has been made freely available online.
'The GLP-1 boom has at least put metabolic health on the radar,' says Dr Murdoch. 'Now we need to give people complete solutions, including lifestyle, not just the drugs.'
Here are the three diets doctors recommend.
Low-carb diet
Key benefits: simple and sustainable
The low-carb diet is proven to get results and can curb food cravings, reverse type 2 diabetes and deliver comparable weight loss to GLP-1s, suggests latest research.
Cutting down on sugar and starchy carbs deprives the body of its primary fuel, glucose. It starts burning body fat instead, leading to weight loss. Blood-sugar levels stabilise, appetite regulates, and insulin levels fall, leading to better metabolic health and lower risk of type 2 diabetes and cardiovascular disease.
Dr Unwin has been spearheading the low-carb approach at his NHS clinic in Southport for the past 13 years, with striking results. 'On average, patients lose 10kg (22lbs) in the first year,' he says. 'We've helped 151 people achieve drug-free diabetes remission. That's 27 per cent of our diabetic population. We've saved £370,000 on diabetes medication.'
In total, 51 per cent of Dr Unwin's patients with type 2 diabetes achieve remission, another 47 per cent get better control over their condition. And over 90 per cent of patients with pre-diabetes return to normal blood-sugar levels.
Dr Unwin's approach has been adopted all over the world, through The Low-Carb Program and a free NHS-approved app.
The method is simple, says Dr Unwin. 'Eat a nutritionally dense diet that doesn't raise your blood sugar.' Officially, low carb means eating less than 130g of carbs a day (for context, one apple is 25g, a bowl of pasta 40g). However, Dr Unwin recommends focusing less on numbers and more on cutting out sugar and starchy carbs, like bread, cereals and potatoes, while increasing protein and green veg. A typical low-carb meal might be baked salmon with asparagus and cauliflower rice.
'When you eat in a way that doesn't spike blood sugar, and includes enough protein, you stay feeling full, partly through natural, GLP-1 production,' explains Dr Unwin.
Kirsten Linaker, 48, turned to the low-carb diet after weight-loss injections failed to help her. 'Dr Unwin gave me simple diet advice and a blood-glucose monitor, so I could see how foods like chocolate spiked my blood sugar,' she says. 'Now, I've lost almost 6st and have gone from size 26 to 14. I'm off my diabetic medication, and my food cravings have gone. I used to sit in bed at night, eating biscuits, now I'm just not hungry anymore. I don't even miss sweet stuff.'
If you're following a low-carb diet, be sure to include nutritious foods, rich in fibre. If you have an existing medical problem, see your GP first.
Keto diet
Key benefit: rapid results
The ketogenic, or 'keto' diet, is a more restrictive, high-fat, even lower carbohydrate approach designed to induce a fat-burning state in the body called ketosis. Followers of the diet aim for 20-50g carbs per day (drastically less than the 130g as on the low carb diet). It's proven to offer immediate weight loss and appetite suppression, along with metabolic-health benefits.
'In my experience, the keto diet gives the same benefits as GLP-1s, such as reduced appetite and elimination of food noise, without the side effects,' says Dr Eric Westman, associate professor of medicine at Duke University and director of the Duke Keto Medicine Clinic.
When carb intake is drastically restricted, the body switches into ketosis, a metabolic state in which it burns fat for fuel, by converting it to ketones. This reduces blood glucose and insulin, and lowers levels of the hunger hormone, ghrelin. People can lose several pounds in the first week, gradually slowing to a more sustainable rate.
Dr Westman's clinical research has shown that a keto diet can put type 2 diabetes into remission. Around 98 per cent of his patients with type 2 diabetes come off insulin. 'Patients typically lose one to two pounds a week,' he says. 'I can safely de-prescribe medications for diabetes, hypertension, heartburn and arthritis.'
A meta-analysis of trials, in Nutrients, found that ketogenic diets gave better weight loss and blood-sugar control than a low-carb diet.
Sharon Grey, 56, was almost 18st and living with type 2 diabetes, Nash (non-alcoholic fatty liver disease), high blood pressure and depression before she began Dr Westman's keto programme (adaptyourlifeacademy.com). After 13 months, her weight had dropped to 12st 8lb. 'I reversed my type 2 diabetes and Nash, and my blood pressure is normal again,' she says. 'My headaches, backache and knee pain improved, my mood is better and I'm taking fewer medications.'
The key to keto success is to keep carbs under 50g a day. Include plenty of protein, says Dr Westman. 'Protein is critical as it helps you feel full, and ensures you lose fat, not muscle,' he says. 'Don't overdo the dietary fat - if you eat too much of it, your body will burn that, rather than body fat.' His top five keto foods are eggs, meat or poultry, seafood, non-starchy veg (like cauliflower or broccoli) and leafy greens.
So when should you choose keto, rather than a low-carb diet? 'Keto isn't always necessary, but in severe cases, it can be beneficial,' says Dr Murdoch. 'The keto diet offers rapid results and some patients feel better on it,' adds Dr Unwin. 'However, it's more complicated than a standard, low-carb diet, and not essential for reversing type 2 diabetes.'
Transitioning to ketosis can trigger temporary fatigue and nausea, called 'keto flu'. If you're on medication, or have a medical condition, only try keto under medical supervision, advises Dr Westman.
Intermittent fasting
Key benefits: cheap and effective
If you don't like calorie counting, focusing on when you eat, rather than what you eat, could be the solution. Intermittent fasting – alternating periods of eating and fasting, such as the popular 5:2 diet – can lead to an average weight loss of five to nine per cent of body weight over three to 12 months, according to research.
'When we don't eat, the body moves into fat-release mode,' explains Dr Murdoch. 'Fasting gives the body longer to use up stored sugar and burn body fat. That's why it improves blood-sugar control, too.'
Among the most effective fasting methods is time-restricted eating (TRE), where you consume your food within a defined window each day, followed by an overnight fast. A study at Manchester Metropolitan University found that just three days on the 16:8 method (eating within an eight-hour window and fasting for 16 hours) significantly improved blood-sugar control in people with type 2 diabetes.
'TRE offers promising benefits for weight loss, glucose regulation and metabolic health – without calorie counting,' says study lead Dr Kelly Bowden Davies. 'While average weight loss is typically less than with GLP-1 drugs, prolonged use of TRE is a cheaper, safer and more accessible alternative – especially when combined with lifestyle changes.'
That's the approach taken by Dr Murdoch with his Metabolic Health 28-Day Plan. It combines time-restricted eating (11am-7pm), focusing on lower-carb (often under 70g a day), high-protein (1-2g per kilo of body weight a day) foods, daily movement (for example, squats while the kettle boils) and seven hours' sleep, presented as a tick list of 10 daily habits.
'People often lose half a stone to a stone in the first month,' says Dr Murdoch. 'Blood pressure, blood sugar, mood and energy all improve. It's as effective as GLP-1s, for a fraction of the cost, and with far better sustainability.'
Donna Brewer, 48, weighed nearly 22st when she started the plan in April. 'I'd gradually gone from a size 14 to a 24. I felt sluggish, tired, anxious, and my blood pressure was dangerously high,' she says. 'After 28 days, I'd lost almost one-and-a-half stone. Now I'm down more than 2st, my waist's shrunk from 130cm to 118cm, and I'm off medication. I feel so much happier and more energetic. It's not like a diet – more a shift in mindset.'
The health risks of GLP-1s
Using GLP-1 drugs without nutrition advice or lifestyle support can lead to malnutrition and even accelerated ageing, caution experts. 'GLP-1s reduce appetite but if you simply eat less of a regular, poor diet, you risk becoming deficient in protein and nutrients – and this drives muscle loss,' says Dr Murdoch. 'We're already seeing muscle loss and then weight regain when people stop taking the drugs.'
An Oxford University review found that most people regain the weight within 10 months of stopping GPL-1s. 'The drugs are only licensed for two years [and many patients give up earlier],' says Dr Murdoch. 'After that, if you haven't changed your habits, the weight comes back – and you've lost muscle along the way, which is hard to get back.'
In a recent clinical trial, 42 per cent of over-60s lost at least 10 per cent of their muscle power – the equivalent of ageing 7.5 years – within six months of taking the GLP-1 drug semaglutide. 'You need to pair these drugs with resistance training and proper nutrition, particularly protein,' says Dr Murdoch.
GLP-1s do have a role to play, say the doctors. 'For people addicted to ultra-processed food or who struggle to give up starchy carbs, GLP-1s can be a temporary tool, if combined with nutritional support,' says Dr Unwin. 'I recently had a 75-year-old patient who lost a stone and a half and came off insulin by combining a GLP-1 with a low-carb diet.'
However, he and other doctors are concerned the drugs are being promoted as a fix-all. 'The way weight-loss drugs are being pushed as a default solution is worrying,' says Dr David Jehring, chairman of the PHC, chief executive of Black Pear Software and creator of Elevate, a new AI personal health coach, soon to be trialled in the NHS. 'GLP-1s are now so widely available, primary care services are being told they don't need to offer dietary interventions.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

After passionately describing 'real stress,' the Fox News host playfully tried the oral device to relax.
After passionately describing 'real stress,' the Fox News host playfully tried the oral device to relax.

Yahoo

time2 hours ago

  • Yahoo

After passionately describing 'real stress,' the Fox News host playfully tried the oral device to relax.

Jesse Watters, the Fox News host known for making up rules about what is and is not 'manly,' sucked on a pacifier Friday while downplaying young adults' stress. On The Five, Watters reacted to the apparent trend of those in their teens and twenties resorting to the infant item to help manage stress levels. TikTok videos show users in China adopting the unconventional approach, with some reporting that it helps reduce the urge to smoke and provides a 'sense of safety from childhood,' the South China Morning Post reported. Watters and co-host Greg Gutfeld didn't see the need.

Sector Spotlight: Trump administration seeks hometown discount from Big Pharma
Sector Spotlight: Trump administration seeks hometown discount from Big Pharma

Business Insider

time2 hours ago

  • Business Insider

Sector Spotlight: Trump administration seeks hometown discount from Big Pharma

Welcome to the latest 'Sector Spotlight,' where The Fly looks at a new industry every week and highlights its happenings. This edition focuses on the pharmaceutical sector following a busy week of earnings and political news. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. PHARMACEUTICAL NEWS: The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, Reuters' Patrick Wingrove and Maggie Fick reported, citing a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries. President Donald Trump said while being interviewed on CNBC earlier this week that separate tariff announcements are coming soon on semiconductor chips and pharmaceuticals. GSK (GSK) announced that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech (BNTX) on, the company will receive an upfront settlement of $370M. GSK will also receive a 1% royalty in respect of US sales of influenza, COVID-19 and related combination mRNA vaccine products by BioNTech and Pfizer (PFE) from the beginning of 2025. These payments are due to GSK in accordance with the terms of its existing license agreement with CureVac. Of the upfront settlement amount, $320m will be in cash. The remainder is attributed to the value of an amendment to GSK's existing agreement with CureVac, which includes a significant reduction in royalties to be paid by GSK on our potential future mRNA influenza, COVID-19 and influenza/COVID-19 combination products. If the pending acquisition of CureVac by BioNTech successfully closes, the mRNA patent litigation between CureVac and BioNTech outside of the US will also be settled. GSK would then be entitled to an additional $130 million in cash and 1% royalty payments in respect of future sales outside of the US by BioNTech and Pfizer. Sales of Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Mounjaro doubled in India in July compared to June, Rishika Sadam and Kashish Tandon of Reuters noted, citing research firm Pharmarack. Demand for anti-obesity drugs has been on an upswing in the country. Novartis (NVS) has made a takeover offer for Avidity Biosciences (RNA), which has a market value of $4.3B, The Financial Times' Oliver Barnes, James Fontanella-Khan and Hannah Kuchler wrote. Avidity, which has three medicines in clinical trials that treat different forms of muscular dystrophy, is working with advisers to assess its options, people familiar with the matter say. The U.S. Department of Health and Human Services announced the beginning of a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority, including the cancellation and de-scoping of various contracts and solicitations. The decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency. 'We reviewed the science, listened to the experts, and acted,' said HHS Secretary Robert F. Kennedy, Jr. 'BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.' The wind-down affects a range of programs including: Cancellation of BARDA's award to Moderna (MRNA) /UTMB for an mRNA-based H5N1 vaccine; Termination of contracts with Emory University and Tiba Biotech; De-scoping of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus; Rejection or cancellation of multiple pre-award solicitations, including proposals from Pfizer , Sanofi Pasteur (SNY), CSL Seqirus, Gritstone, and others, as part of BARDA's Rapid Response Partnership Vehicle and VITAL Hub, and; Restructuring of collaborations with DoD-JPEO, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca (AZN), and HDT Bio. Bristol Myers (BMY) announced that the FDA has accepted the supplemental biologics license application for Breyanzi as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy. EARNINGS RECAP: Eli Lilly's second quarter results beat expectations and the company raised its full-year outlook as well. However, shares of the company were down 7% on Thursday morning after the company reported data from a late-stage trial of its under-development obesity pill. 'Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines,' said David Ricks, Lilly chair and CEO. 'Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health-including Mounjaro's demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and strong data for our oral incretin, orforglipron, in obesity. We also expanded manufacturing capacity to meet increasing demand and invested in key R&D initiatives to support our long-term growth.' Leerink downgraded Eli Lilly to Market Perform from Outperform with a price target of $715, down from $944. Following 'disappointing' initial results for orforglipron, the company's oral GLP-1, the firm is lowering its long-term projections and notes that its 'investment thesis has changed' as it no longer expects upward pressure on long-term consensus expectations. The firm also noted that Lilly's major competitor Novo Nordisk is struggling and may need to continue to use price to compete in its duopoly while the firm expects growing competition from various competitors starting late decade. Conversely, JPMorgan views the post-earnings selloff in shares of Eli Lilly as providing a 'compelling' entry point. The Q2 report came in well ahead of consensus estimates and Lilly is raised guidance, which should dispel some weight loss market concerns, the analyst tells investors. However, the firm says the bigger focus was on orforglipron's Phase 3 obesity data where weight loss came in slightly below expectations. JPMorgan does not see 1-2 percentage points lower weight loss as meaningfully changing the use case for orforglipron. It keeps an Overweight rating on Lilly shares with a $1,100 price target. Pfizer also experienced a beat and raise quarter in Q2. Although, the company did note that its FY25 guidance does not anticipate any share repurchases. On the company's Q2 earning call, Pfizer noted that the company's guidance 'absorbs the impact of the currently imposed tariffs from China, Canada and Mexico as well as potential price changes this year based on the letter received on July 31 from President Trump.' Later in the call, Pfizer CEO Albert Bourla said the company is 'in very active discussions' at 'the highest levels of this government.' Bourla added: 'I discussed myself with the president after he sent the letter to me and all the others. We discussed a lot with the Secretary Kennedy, we discussed a lot with Doctor Post who is responsible for implementing a lot of these things. And I would say only that these discussions are extremely productive. I think we understand where the president comes from, and we are engaging in a productive way to find a solution. But because we are in active discussions, it's inappropriate for me to start providing more details because I don't want to say things while discussing with them. So I understand that many others may have questions about that, and I'm not sure I can give more information than what I just told you. That we had a letter that says a base of what the president wants. The letter asks a lot from us. But we are engaged in productive discussions with them.' Following the report, Citi analyst Geoff Meacham raised the firm's price target on Pfizer to $26 from $25 and reiterated a Neutral rating on the shares. The company reported strong Q2 results, but policy headwinds warrant a continued cautious stance, the analyst told investors.

I had the worst diarrhea ever on a plane — they had to land and cancel the flight
I had the worst diarrhea ever on a plane — they had to land and cancel the flight

Yahoo

time3 hours ago

  • Yahoo

I had the worst diarrhea ever on a plane — they had to land and cancel the flight

An airline was forced to 86 a flight after this gal took a terrible No. 2. Meghan Reinertsen swears she isn't a monster. The blond is simply a frequent flyer whose sudden bout with uncontrollable diarrhea allegedly caused United Airlines to call off a takeoff so that Hazmat specialists could clean up her massive blow-up. 'I single-handedly got a flight out of Indianapolis cancelled,' an apologetic Reinertsen announced to over 20 million TikTok viewers. 'If that flight cancellation changed the trajectory of your life in a really negative way, I'm so sorry.' 'But it wasn't without pain and suffering.' Reinertsen, a nanny and budding actress, explained that she was traveling from Portugal back to the US for a film premiere when 'a disturbance deep, deep' in her bowels ignited. 'Something is brewing,' she remembered thinking. 'Something is happening that I am not prepared to deal with.' That something was food poisoning. It was a nasty, not-so-little bug the belle picked up after eating an undercooked hamburger the night before her flight. Although food poisoning is rarely fatal, according to the Cleveland Clinic, symptoms of the illness, including vomiting and diarrhea, can feel deadly. An Etihad Airways passenger had to be wheeled off the aircraft after eating a 'smelly' in-flight meal and throwing up over two dozen times during a six-hour 'flight from hell.' And a recent Delta Airlines flight from Detroit to Amsterdam was forced to make an emergency landing in New York, when several passengers exhibited signs of food poisoning from the reportedly 'spoiled' grub served while at 30,000 feet. Luckily for Reinertsen, her rumbling belly didn't cause the plane to make an unscheduled stop. It did, however, stop her fellow passengers from using the bathroom. 'I'm full body sweating, I'm crying, my insides are cramping,' she recalls of the moments leading up to the explosion, adding she feared a public accident would erupt if she didn't high-tail it to the toilet — even though the seatbelt sign was still illuminated. 'I couldn't let that happen to me,' said the hapless sweetheart, who then admitted, 'for the next 20 minutes, I have more diarrhea than any human should have in their life.' Amid her pooping nightmare in the cramped airplane commode, vomit also sprang up, prompting Reinertsen to call a flight attendant for help. After barfing in a bag provided by the cabin crew member, Reinertsen remained in the lavatory, spewing and defecating, for the duration of the flight. The attendant informed her that the next trip the Airbus was scheduled to make had been canceled. Reinertsen was ultimately wheelchair-escorted off the plane, which was then parked for deep cleaning, and left to fend for herself at baggage claim. Sadly, her misadventures didn't end there. She also suffered from another round of diarrhea in her hotel bed. But the shame of soiling the establishment's sheets apparently didn't compare to the embarrassment of grounding an airplane. 'They canceled that flight because of me. The Hazmat team [had] to come in and clean it, because [they didn't] know if I'd brought [a disease] back from Portugal,' Reinertsen groaned. 'I am a biohazard,' she self-deprecatingly teased. 'I am patient Zero.' Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store